177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

被引：0
|
作者：
Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
机构：
[1] University Hospital of Muenster,Department of Nuclear Medicine
[2] University Hospital of Muenster,Department of Urology
[3] University Hospital of Bonn,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
PSMA-617; Radioligand therapy; mCRPC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：166 / 167
页数：1
相关论文
共 50 条
  • [41] Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
    Jadvar, Hossein
    Iravani, Amir
    Bodei, Lisa
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1851 - 1854
  • [42] Radioligand Therapy with 7.4 GBq 177-Lu-PSMA-617 in patients with mCRPC in a 6 weekly interval
    Braeuer, A.
    Seifert, R.
    Gonzalez, J.
    Schrader, A.
    Schaefers, M.
    Boegemann, M.
    Rahbar, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S125 - S126
  • [43] PSMA-ligand uptake in posttherapeutic 177Lu-PSMA-617 scintigraphy to predict PSA response in patients with advanced mCRPC
    Werner, Rudolf
    Thiele, Johannes
    Ross, Tobias
    Bengel, Frank
    Derlin, Thorsten
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [44] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [45] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [46] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) : 85 - 90
  • [47] A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT)
    Holzgreve, Adrien
    Delker, Astrid
    Ells, Zachary
    Brosch-Lenz, Julia
    Zhu, Shaojun
    Lira, Stephanie
    Nikitas, John
    Grogan, Tristan
    Elashoff, David
    Unterrainer, Lena M.
    Dahlbom, Magnus
    Allen-Auerbach, Martin S.
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
    Patel, P.
    McCall, K.
    MEDICAL PHYSICS, 2022, 49 (06) : E811 - E812
  • [49] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 : 257S - 262S
  • [50] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
12345